Dr
George
Bebawy
I am George Bebawy, lecturer of pharmaceutics, Faculty of Pharmacy, Alexandria University, Egypt. Primarily, I was graduated back home in Egypt in the Faculty of Pharmacy class 2012, and worked as demonstrator at my home institute, teaching pharmaceutics for undergraduate pharmacy students. I was fascinated by research, so I got an extensive 3 years master research based degree, my research was focused mainly on developing suitable dosage forms for paediatric use, including converting of the commercial risperidone oral solution, into a taste masked orally disintegrating minitablet formulation. Thereafter, I travelled to the United Kingdom to get my PhD degree in pharmaceutical science. I joined school of pharmacy University of Nottingham, through which I got my PhD. My research project was mainly on targeting cancer and optimising nanoparticle formulations for betted therapeutic effect. Through my PhD, novel orlistat LDL-like NPs were evaluated for targeting breast cancer. I am currently working as PDRA at school of Pharmacy, UCL. In the current project, we will investigate virus-like-particles (VLPs) formulations that are suitable for sublingual and buccal administration. A range of excipients will be used to optimise formulations and in vitro tests will be conducted to assess the stability of VLPs upon formulation and storage. VLPs will be spray-dried to produce thermostable preparations. VLP stability upon spray-drying will be assessed. In vivo studies will be conducted to evaluate the immunogenicity of VLPs when administered under the tongue and when injected
I am interested in the field of vaccines development and formulation, against many infectious agents including Zoonotic diseases. My research focuses mainly on enhancing the vaccines activity through formulations, particularly through the investigation of various adjuvants and techniques to enhance the vaccines stability and immunogenicity. I am highly interested as well in the field of formulations technology development, as an optimum formulation in most of cases guarantee an optimum effect clinically.
In the current project, we will investigate virus-like-particles (VLPs) formulations that are suitable for sublingual and buccal administration. A range of excipients will be used to optimise formulations and in vitro tests will be conducted to assess the stability of VLPs upon formulation and storage. VLPs will be spray-dried to produce thermostable preparations. VLP stability upon spray-drying will be assessed. In vivo studies will be conducted to evaluate the immunogenicity of VLPs when administered under the tongue and when injected.